

12 August 2025

<u>Lenalidomide Viatris (lenalidomide) Capsules</u> - Alternative Registered Foils

Dear Healthcare Professional,

We are writing to provide you with an important update regarding Lenalidomide Viatris (lenalidomide) Capsules (provisional consent) sponsored by Viatris Ltd.

Further to our previous Dear Healthcare Professional letter (distributed on 14th of July 2025) regarding additional registered foils for Lenalidomide Viatris, we wish to advise that additional blister strips sourced from European markets will now be placed into New Zealand-registered cartons. These include newly registered foils for the **5 mg** and **15 mg** strengths. For your reference, images of the additional registered alternative blister foils are included in the table below.

As previously noted, there is no change to the capsule formulation or appearance. The only variation is the foil packaging, which may:

- Appear in different languages, and/or
- Display an alternate trade name from 'Lenalidomide Viatris'.

These additional foils are approved and will be available in the New Zealand market. Both existing and European blisters may be distributed concurrently in the short term.

For further details, the full letter is available at: https://www.medsafe.govt.nz/safety/DHCPLetters/LenalidomideViatris14July2025.pdf

Adverse Event Reporting & Medical Enquiries

Please report any suspected adverse events via email to Medinfo_anz@viatris.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) online at https://pophealth.my.site.com/carmreportnz/s/ reporting or by email to CARMreport@health.govt.nz. Please direct any medical enquiries to Viatris or report any suspected adverse drug reactions to Viatris via telephone on 0800 168 169 or by email at medinfo_anz@viatris.com.

Yours sincerely,

Manar Al-Murrani Senior Medical Affairs Specialist

Manar Al-Murrani



Foil Overview

